This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Analysts' Actions: Allergan, Broadcom, Clovis, Centene, Devon Energy

NEW YORK (TheStreet) -- RATINGS CHANGES

Allergan (AGN - Get Report) was downgraded at Credit Suisse to neutral from outperform. Twelve-month price target is $190. Risk/reward is balanced, following the latest bid from Valeant (VRX), Credit Suisse said.

Big Lots (BIG) was downgraded to hold at TheStreet Ratings.

Broadcom (BRCM - Get Report) was downgraded at Stifel to hold from buy, Stifel Nicolaus said. Valuation call, based on a 12-month price target of $35, Stifel Nicolaus said.

Broadcom was upgraded at Wedbush to outperform from neutral. Twelve-month price target is $43. Company is looking to sell or wind down the cellular baseband business, which has been an overhang, Wedbush said.

Chico's FAS (CHS) was downgraded to hold at TheStreet Ratings.

Clovis (CLVS) was downgraded at Citigroup to neutral. Twelve-month price target is $53. Company could face increased competition from AstraZeneca (AZN), Citi said.

Centene (CNC) was downgraded at Citigroup to sell. Takeover rumors will likely fizzle out, Citi said.

Devon Energy (DVN) was upgraded at Wells Fargo to outperform from market perform. Production visibility is improving, Wells Fargo said.

Editor's note: To see analysts' stock comments and changes to price targets and earnings estimates, go to "Street Notes" which is available only to Real Money subscribers. To find out how to become a subscriber, please click here.


WATCH: More market update videos on TheStreet TV | More videos from Ruben Ramirez

Follow TheStreet on Twitter and become a fan on Facebook.

>>Read More: Greenberg: Apple's Latest Ad-Stravaganza

This article was written by a staff member of TheStreet.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AGN $307.51 0.00%
BRCM $52.28 0.00%
AAPL $126.44 0.00%
FB $87.28 0.00%
GOOG $523.40 0.00%

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs